Hyperprolactinemia
📧 Sign up to get email alerts when something new happens for Hyperprolactinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-05-16Clinical Trial Update: Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia [NA]
A completed double-blind, placebo-controlled trial evaluating adjunctive aripiprazole for symptomatic hyperprolactinemia in premenopausal wo…
-
CLINICAL_TRIALS trial_result · 2016-09-07Clinical Trial Update: Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
The University of Zurich reports completion of a clinical trial update on a mathematical model of the human menstrual cycle and its implicat…
-
CLINICAL_TRIALS trial_result · 2015-05-28Clinical Trial Update: Aripiprazole and Prolactin Study [Phase 4]
Phase 4 clinical trial update on aripiprazole assessing prolactin levels in hyperprolactinemia; the study has completed.
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia [Phase 2]
Phase 2 clinical trial of Peony-Glycyrrhiza Decoction (PGD) for antipsychotic-induced hyperprolactinemia in schizophrenia has completed.
-
FDA approval · 2015-04-15FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for bromocriptine mesylate (Padagis US LLC).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-02-13FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Bromocriptine Mesylate by Mylan Pharmaceuticals Inc.
-
FDA approval · 2014-11-26FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for bromocriptine mesylate submitted by ANI Pharmaceuticals, Inc. This action updates the regula…
-
CLINICAL_TRIALS trial_result · 2014-10-23Clinical Trial Update: The Luveris In Vitro Fertilization Trial [Phase 4]
Phase 4 trial of Luveris in vitro fertilization has been terminated; results posted in 2014.
-
FDA approval · 2014-08-26FDA Approved: CABERGOLINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for cabergoline submitted by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2014-03-24Clinical Trial Update: Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
Pfizer-sponsored study evaluated cabergoline for compliance with risk minimization activities. The trial, involving Parkinson's disease and …
-
FDA approval · 2014-02-27FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Bromocriptine Mesylate from ANI Pharmaceuticals, Inc., resulting in an updated approval for …
-
CLINICAL_TRIALS trial_result · 2013-10-08Clinical Trial Update: Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients [Phase 4]
Phase 4 clinical trial evaluating color Doppler analysis of uterine and intraovarian blood flow before and after cabergoline treatment in hy…
-
FDA approval · 2013-07-31FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for Bromocriptine Mesylate, resulting in updated labeling for the product.
-
FDA label_change · 2013-06-12FDA Approved: CYCLOSET — Supplemental Application (Avvisto Therapeutics LLC)
The FDA approved a supplemental application for CYCLOSET (bromocriptine mesylate) submitted by Avvisto Therapeutics LLC. The action involves…
-
FDA approval · 2013-03-14FDA Approved: CYCLOSET — Supplemental Application (Avvisto Therapeutics LLC)
FDA approved a supplemental application for CYCLOSET (bromocriptine mesylate) from Avvisto Therapeutics LLC.
-
FDA approval · 2012-08-13FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for bromocriptine mesylate (ANDA 078899) submitted by Zydus Pharmaceuticals USA Inc., granting regul…
-
CLINICAL_TRIALS research · 2011-11-01Clinical Trial Update: Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients [Phase 1]
Phase 1 clinical trial evaluating turmeric's effect on serum prolactin levels and adenoma size in prolactinoma patients.
-
FDA approval · 2011-10-26FDA Approved: CABERGOLINE — Supplemental Application (SOLA Pharmaceuticals, LLC)
FDA approved SOLA Pharmaceuticals’ supplemental application for cabergoline (generic), granting approval for commercialization of the generi…
-
FDA approval · 2011-10-26FDA Approved: CABERGOLINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for cabergoline submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2011-08-11FDA Approved: CABERGOLINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for cabergoline from Mylan Pharmaceuticals Inc., updating the product's labeling.
-
FDA approval · 2011-07-18FDA Approved: CABERGOLINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for cabergoline filed by Mylan Pharmaceuticals Inc., resulting in a revised label and potential expa…
-
CLINICAL_TRIALS trial_result · 2011-03-11Clinical Trial Update: The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
A clinical trial update investigates the association between dopamine agonists and cardiac valvulopathy, fibrosis, and other cardiopulmonary…
-
CLINICAL_TRIALS trial_result · 2009-08-07Clinical Trial Update: Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine
A completed clinical trial evaluated prolactin changes in patients with antipsychotic-induced hyperprolactinemia after switching to quetiapi…
-
CLINICAL_TRIALS trial_result · 2009-01-12Clinical Trial Update: Endometriosis Patients Undergoing Quinagolide Treatment [Phase 4]
A Phase 4 clinical trial evaluating quinagolide for endometriosis and hyperprolactinemia has completed.
-
FDA approval · 2008-10-01FDA Approved: BROMOCRIPTINE MESYLATE — Original Application (Padagis US LLC)
FDA approved Padagis US LLC's original generic application for bromocriptine mesylate. This approval provides a generic version of bromocrip…